 |
|
|
| |
The bispecific anti-FGFR1/KLB agonist antibody
bFKB1 attenuates non-alcoholic
steatohepatitis and atherosclerosis in Ldlr-/-.Leiden mice
|
| |
| |
AASLD 2022 nov 4-8
José A. Inia1,2,3, Anita M. van den Hoek1, Geurt Stokman1, Joline Attema1, Christa de Ruiter1, Martien Caspers4, Lars Verschuren4,
J. Wouter Jukema2,3, Maria Wilson5, Hans M.G. Princen1, Mark Chen5,6, Martine C. Morrison1
1 Metabolic Health Research, TNO Leiden, The Netherlands, 2 Department of Cardiology and 3 Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center
Leiden, The Netherlands, 4 Microbiology and Systems Biology, TNO Zeist, The Netherlands, 5 Genentech, South San Francisco, USA, 6 Takeda Pharmaceuticals, San Diego
|
| |
|
|
|
|
|
